Dr.ObesityLA said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

I would rather be corrected than agreed with, if it comes to it.

SandraNC_45 said:

The mechanism is more central than most summaries suggest.

This answered a question I did not know how to ask. I will report back once I have actually tried it.

Dr.ObesityLA said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

I would rather be corrected than agreed with, if it comes to it.

One concrete data point for the thread. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

I would rather be corrected than agreed with, if it comes to it.

Moderator note: the sourcing question belongs in the vendor section and has been split out.